CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth
CorMedix (CRMD) has entered into a definitive agreement to acquire substantially all assets from Heron Therapeutics. The acquisition includes both commercial and pipeline assets intended to complement CorMedix's existing portfolio. Management expects the integration to create significant operational synergies valued between $45 million and $60 million annually. The transaction is projected to have a substantial impact on long-term growth, with management forecasting that Heron's assets will contribute between $125 million and $150 million in pro forma revenue by 2027. This strategic move aims to expand CorMedix's market presence through highly complementary product offerings.
Topics: Asset Acquisition Corporate Strategy Mergers and Acquisitions